Glutamate inhibitors or glutamate antagonist drugs inhibit the action of neurotransmitter glutamate on neurons and are used to treat amyotrophic lateral sclerosis (ALS), also known as motor neuron disease or Lou Gehrig’s disease, caused by loss of or damage to motor neurons.

Current pharmacological options for MDD include the serotonin-selective reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants (eg, bupropion, mirtazapine), tricyclic antidepressants (TCAs), …

2024年6月21日 · Glutamate antagonists are a fascinating and crucial class of drugs in the field of neuroscience and pharmacology. Understanding how these agents work and their applications can provide valuable insights into their therapeutic potential and the mechanisms underlying various neurological disorders.

NMDA (N-methyl-D-aspartate) receptor antagonists are a class of drugs that may treat memory loss and brain damage associated with Alzheimer’s disease. NMDA receptor allows the binding of the excitatory neurotransmitter glutamate to its site.

Glutamate receptors are responsible for the glutamate-mediated postsynaptic excitation of neural cells, and are important for neural communication, memory formation, learning, and regulation. Glutamate receptors are implicated in a number of neurological conditions .

Glutamate receptor antagonists can be broadly divided into two types: agents that block the NMDA receptor and those that block the AMPA receptor. Antagonists of the NMDA receptor act either by competitive antagonism at the glutamate-binding site or by noncompetitive antagonism at the glycine, phencyclidine (PCP)-, and magnesium-binding sites.

Glutamate antagonists work by inhibiting the activity of glutamate receptors in the brain. These receptors are broadly classified into two main subtypes: N-methyl-D-aspartate (NMDA) and 3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors.

Ketamine is a voltage-dependent NMDA receptor antagonist that inhibits the flux of cations (calcium, sodium) in the presence of the coagonists glutamate and glycine.

2024年4月11日 · The glutamate pathway antagonist riluzole is the first medication that has shown efficacy in extending life in amyotrophic lateral sclerosis (ALS). The American Academy of Neurology (AAN)...

Serotonin reuptake inhibitors and benzodiazepines are evidence-based pharmacological treatments for Anxiety Disorders targeting serotonin and GABAergic systems, respectively. Although clearly effective, these medications fail to improve anxiety symptoms in a significant proportion of patients.